Literature DB >> 21396178

Long-term simvastatin attenuates lung injury and oxidative stress in murine acute lung injury models induced by oleic Acid and endotoxin.

Neriman Defne Altintas1, Pergin Atilla, Alper Bektas Iskit, Arzu Topeli.   

Abstract

BACKGROUND: 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors have several pleiotropic effects, including anti-inflammatory properties, and are reported to improve endothelial functions. Pathophysiologically, acute lung injury (ALI) is caused by a severe inflammatory response and endothelial dysfunction.
OBJECTIVE: To investigate the effects of simvastatin (an HMG-CoA reductase inhibitor) on oxidative stress and lung histopathology in 2 murine models of ALI, induced by oleic acid and endotoxin.
METHODS: The mice were randomly divided into 2 groups: one received 2 mg/kg/d intraperitoneal simvastatin for 15 days. Then the groups were further divided into 3, which received saline, oleic acid, or endotoxin. Four hours after inducing ALI we obtained lung samples for histopathology analysis, myeloperoxidase, glutathione, and malondialdehyde measurement, and blood samples for malondialdehyde measurement.
RESULTS: Endotoxin and oleic acid lung injury increased tissue myeloperoxidase (P = .009 for both), decreased tissue glutathione (P = .02 and P = .009, respectively), and increased tissue malondialdehyde (P = .009 for both), compared to the control group. Simvastatin decreased myeloperoxidase only in the oleic acid group (P = .01). Simvastatin increased glutathione (P = .005 and P = .003, respectively) and lowered malondialdehyde in both the endotoxin and oleic acid groups (P = .003 for both). Histopathology revealed that simvastatin protected the lung tissue in both ALI models, but the protection was greater in the endotoxin group.
CONCLUSIONS: Pretreatment with simvastatin decreased the severity of ALI in oleic acid and endotoxin ALI models, by decreasing inflammation and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396178     DOI: 10.4187/respcare.00770

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Enhanced Resolution of Hyperoxic Acute Lung Injury as a result of Aspirin Triggered Resolvin D1 Treatment.

Authors:  Ruan Cox; Oluwakemi Phillips; Jutaro Fukumoto; Itsuko Fukumoto; Prasanna Tamarapu Parthasarathy; Stephen Arias; Young Cho; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Respir Cell Mol Biol       Date:  2015-09       Impact factor: 6.914

2.  Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Authors:  Svenja Nölting; Alessio Giubellino; Yasin Tayem; Karen Young; Michael Lauseker; Petra Bullova; Jan Schovanek; Miriam Anver; Stephanie Fliedner; Márta Korbonits; Burkhard Göke; George Vlotides; Ashley Grossman; Karel Pacak
Journal:  Endocrinology       Date:  2014-04-24       Impact factor: 4.736

3.  Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy.

Authors:  Benjamin B Davis; Amir A Zeki; Jennifer M Bratt; Lei Wang; Simone Filosto; William F Walby; Nicholas J Kenyon; Tzipora Goldkorn; Edward S Schelegle; Kent E Pinkerton
Journal:  Eur Respir J       Date:  2012-11-22       Impact factor: 16.671

4.  Arctigenin Protects against Lipopolysaccharide-Induced Pulmonary Oxidative Stress and Inflammation in a Mouse Model via Suppression of MAPK, HO-1, and iNOS Signaling.

Authors:  Wen-zhou Zhang; Zheng-kui Jiang; Bao-xia He; Xian-ben Liu
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 5.  Nanomedicine-Based Therapeutics to Combat Acute Lung Injury.

Authors:  Youbin Cui; Wanguo Liu; Shuai Bian; Hongfei Cai; Chunsheng Xiao
Journal:  Int J Nanomedicine       Date:  2021-03-18

6.  Influence of rosuvastatin treatment on cerebral inflammation and nitro-oxidative stress in experimental lung injury in pigs.

Authors:  Jens Kamuf; Andreas Garcia Bardon; Alexander Ziebart; Robert Ruemmler; Johannes Schwab; Mobin Dib; Andreas Daiber; Serge C Thal; Erik K Hartmann
Journal:  BMC Anesthesiol       Date:  2021-09-13       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.